Skip to main content
. 2021 Mar 4;15(3):e0009055. doi: 10.1371/journal.pntd.0009055

Table 4. DALY estimates for ZIKV.

YLLacute YLDacute YLLGBS YLDGBS YLLCZS YLDCZS YLDcare YLDEPL TOTAL
AFRO - 1
(1–2)
- - 92
(0–276)
146
(0–219)
48
(0–90)
- 287
(1–403)
AMRO 40
(40–60)
96
(23–197)
108
(0–206)
5
(0–289)
12,236
(9,384–45,632)
22,734
(178–40,958)
7,460
(118–17,364)
16
(4–59)
42,690
(10,058–77,884)
EMRO - - - - - - - - -
EURO - - - - 0
(0–92)
73
(0–73)
24
(0–30)
- 97
(0–104)
SEARO - - - - 0
(0–92)
73
(0–73)
24
(0–30)
- 97
(0–173)
WPRO - 2
(2–5)
- 0
(0–15)
276
(0–1,104)
512
(0–951)
168
(0–391)
0
(0–1)
958
(2–1,812)
TOTAL 40
(40–60)
100
(26–203)
108
(0–206)
5
(0–304)
12,604
(9,384–47,104)
34,772
(178–42,275)
7,724
(118–17,364)
16
(4–61)
44,130
(10,061–80,407)

AFRO, WHO Africa region; AMRO, WHO Americas region; care, caregiver impact; CZS, congenital Zika syndrome; DALY, disability-adjusted life year; EMRO, WHO Eastern Mediterranean region; EPL, early pregnancy loss; EURO, WHO European region; GBS, Guillain–Barré syndrome; SEARO, WHO Southeast Asia region; WPRO, Western Pacific region; YLD, years lost to disability; YLL, years of life lost; ZIKV, Zika virus.